Advertisement

Patient-Driven Drug Development

  • Jessica FlaniganEmail author
Chapter
Part of the Philosophy and Medicine book series (PHME, volume 122)

Abstract

Patient-driven drug development is an emerging approach to pharmaceutical research that is forged in rare-disease communities and patient advocacy networks. Patients and their advocates increasingly engage in drug discovery and influence early-stage drug research as clinical trial participants or through compassionate-use programs. Some advocacy groups and patients also influence which therapies are developed by financing promising treatments that otherwise would not secure funding. Though some critics of patient-driven drug development worry about the ethical and scientific implications of this new approach to research, it also has several advantages over the current system. In this essay I argue that patient-driven drug development is morally permissible.

Keywords

Drug Development Experimental Drug Clinical Trial Participant Venture Philanthropy Unapproved Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. “About | iCancer”. 2015. http://icancer.org.uk/about/. Accessed 27 Apr 2015.
  2. Carroll, J. 2015, January 20. CytRx Surges after FDA Lifts a Partial Hold on Late-Stage Cancer Drug. Fierce Biotech. http://www.fiercebiotech.com/story/cytrx-surges-after-fda-lifts-partial-hold-late-stage-cancer-drug/2015-01-20. Accessed 29 Apr 2015.
  3. Cha, A.E. 2014, March 23. Crowdsourcing Medical Decisions: Ethicists Worry Josh Hardy Case May Set Bad Precedent. The Washington Post.Google Scholar
  4. Committee on Bioethics. 1995. Informed Consent, Parental Permission, and Assent in Pediatric Practice. Pediatrics 95(2): 314–317.Google Scholar
  5. Daniels, N. 2001. Justice, Health, and Healthcare. The American Journal of Bioethics 1(2): 2–16.CrossRefGoogle Scholar
  6. Darrow, J.J., A. Sarpatwari, J. Avorn, and A.S. Kesselheim. 2015. Practical, Legal, and Ethical Issues in Expanded Access to Investigational Drugs. The New England Journal of Medicine 372(3): 279–286. doi: 10.1056/NEJMhle1409465.CrossRefGoogle Scholar
  7. deBronkart, D. 2013. How the E-Patient Community Helped Save My Life: An Essay by Dave deBronkart. British Medical Journal 346: f1990.CrossRefGoogle Scholar
  8. DiMasi, J.A., R.W. Hansen, and H.G. Grabowski. 2003. The Price of Innovation: New Estimates of Drug Development Costs. Journal of Health Economics 22(2): 151–185.CrossRefGoogle Scholar
  9. Dwamena, F., M. Holmes-Rovner, C.M. Gaulden, S. Jorgenson, G. Sadigh, A. Sikorskii, S. Lewin et al. 2012. Interventions for Providers to Promote a Patient-Centred Approach in Clinical Consultations. In Cochrane database of systematic reviews, ed. The Cochrane Collaboration. Chichester: Wiley. http://doi.wiley.com/10.1002/14651858.CD003267.pub2. Accessed 11 Aug 2016.
  10. Epstein, S. 1995. The Construction of Lay Expertise: AIDS Activism and the Forging of Credibility in the Reform of Clinical Trials. Science, Technology & Human Values 20(4): 408–437.CrossRefGoogle Scholar
  11. Flanigan, J. 2012. Three Arguments against Prescription Requirements. Journal of Medical Ethics 38(10): 579–586.CrossRefGoogle Scholar
  12. Frydman, G.J. 2009. Patient-Driven Research: Rich Opportunities and Real Risks. Journal of Participatory Medicine 1(1): e12.Google Scholar
  13. Grabowski, H.G., and J.M. Vernon. 1983. The Regulation of Pharmaceuticals: Balancing the Benefits and Risks. Washington, DC: American Enterprise Institute for Public Policy Research.Google Scholar
  14. Grabowski, H.G., J.M. Vernon, and L.G. Thomas. 1978. Estimating the Effects of Regulation on Innovation: An International Comparative Analysis of the Pharmaceutical Industry. Journal of Law and Economics 21(1): 133–163.CrossRefGoogle Scholar
  15. Greenhouse, L. 2008, January 15. Justices Won’t Hear Appeal on Drugs for Terminally Ill. The New York Times.Google Scholar
  16. Hinkes-Jones, L. 2015, January 5. Stop Subsidizing Big Pharma. The New York Times. Google Scholar
  17. Huebner, J.M. 2013. Moral Psychology and the Intuition That Pharmaceutical Companies Have a ‘Special’ Obligation to Society. Journal of Business Ethics 122(3): 501–510.Google Scholar
  18. Jensen, E.J. 1987. Research Expenditures and the Discovery of New Drugs. The Journal of Industrial Economics 36(1): 83–95.CrossRefGoogle Scholar
  19. Kesselheim, A.S., and J.J. Darrow. 2015. FDA Designations for Therapeutics and Their Impact on Drug Development and Regulatory Review Outcomes. Clinical Pharmacology and Therapeutics 97(1): 29–36.CrossRefGoogle Scholar
  20. Lichtenberg, F.R., and J. Waldfogel. 2008. Does Misery Love Company–Evidence from Pharmaceutical Markets before and after the Orphan Drug Act. Michigan Telecommunications and Technology Law Review 15: 335.Google Scholar
  21. Marcus, A.D. 2010. The Loneliness Of Fighting A Rare Cancer. Health Affairs 29(1): 203–206.CrossRefGoogle Scholar
  22. ———. 2015a, March 2. Deaf or Death? In Drug Trial, Parents Weigh Life vs. Hearing Loss. Wall Street Journal.Google Scholar
  23. ———. 2015b. Niemann-Pick Type C: A Fight to Save Children with a Drug. The Wall Street Journal. http://on.wsj.com/1due624. Accessed 10 Mar 2015.
  24. Masters, A. 2015. A Plutocratic Proposal. Mosaic. http://mosaicscience.com/story/plutocratic-proposal. Accessed 7 Apr 2015.
  25. Morrow, K.J. 2015, April 25. Drug Development in the Age of Social Media. Life Science Leader.Google Scholar
  26. Peltzman, S. 1973. An Evaluation of Consumer Protection Legislation: The 1962 Drug Amendments. Journal of Political Economy 81(5): 1049–1091.CrossRefGoogle Scholar
  27. Pollack, A. 2007, August 8. Court Rejects the Right to Use Drugs Being Tested. The New York Times. Google Scholar
  28. Salmon, F. 2014, August 24. The Ice Bucket Challenge Isn’t Going Away: But Giving Money to Disease-Specific Charities Is Still a Bad Idea. Slate. http://www.slate.com/articles/business/moneybox/2014/08/als_ice_bucket_challenge_giving_money_to_disease_specific_charities_is_a.html. Accessed 29 Apr 2015.
  29. Sanghavi, D.M. 2013, October 31. How Dying Patients Get Access to Experimental Drugs. The New York Times. Google Scholar
  30. Scherer, F.M. 2000. The Pharmaceutical Industry. In Handbook of Health Economics, ed. A.J. Culyer and J.P. Newhouse, 1297–1336. 1st edition. Elsevier. http://www.sciencedirect.com/science/article/pii/S1574006400800384. Accessed 11 Aug 2016.
  31. Sofer, G.J. 2008, December 30. The FDA Is Killing Crohn’s Patients. Wall Street Journal. Google Scholar
  32. Thadhani, R. 2006. Formal Trials versus Observational Studies. In Fabry Disease: Perspectives from 5 Years of FOS, ed. A. Mehta, M. Beck, and G. Sunder-Plassmann. Oxford: Oxford PharmaGenesis.Google Scholar
  33. Thomas, G. 2014, February 7. Oakland Pediatrician Opens Her Home To Patients. NBC Bay Area.Google Scholar
  34. Topol, E. 2015. The Patient Will See You Now: The Future of Medicine Is in Your Hands, 1st ed. Basic Books, New York.Google Scholar
  35. Volokh, E. 2007. Medical Self-Defense, Prohibited Experimental Therapies, and Payment for Organs. Harvard Law Review 20: 1813–1846.Google Scholar
  36. Wiggins, S.N. 1981. Product Quality Regulation and New Drug Introductions: Some New Evidence from the 1970s. The Review of Economics and Statistics 63(4): 615–619.CrossRefGoogle Scholar
  37. Yin, W. 2008. Market Incentives and Pharmaceutical Innovation. Journal of Health Economics 27(4): 1060–1077.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2017

Authors and Affiliations

  1. 1.The Jepson School of Leadership StudiesThe University of RichmondRichmondUSA

Personalised recommendations